What's coming? Pazdur, Marks and Woodcock discuss FDA changes
Three of the FDA’s directors — Richard Pazdur, Peter Marks and Janet Woodcock — took the stage Wednesday at Prevision Policy’s Biopharma Congress to discuss all things FDA: from why the agency is viewed more positively now than in the past to what needs to happen in each of their centers.
CDER director Woodcock said that the difference between years past, when FDA was viewed negatively, and now is that there has been a sort of scientific revolution, with biology being harnessed in novel ways and investments at NIH paying off.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.